[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR036276A1 - Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma - Google Patents

Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma

Info

Publication number
AR036276A1
AR036276A1 ARP020103150A ARP020103150A AR036276A1 AR 036276 A1 AR036276 A1 AR 036276A1 AR P020103150 A ARP020103150 A AR P020103150A AR P020103150 A ARP020103150 A AR P020103150A AR 036276 A1 AR036276 A1 AR 036276A1
Authority
AR
Argentina
Prior art keywords
glaucoma
compound
prostaglandine
ceto
treatment
Prior art date
Application number
ARP020103150A
Other languages
English (en)
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR036276A1 publication Critical patent/AR036276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee el uso de un compuesto 15-ceto-prostaglandina que tiene una estructura cíclica al final de la cadena omega para preparar una composición oftálmica para tratar hipertensión arterial y glaucoma de un mamífero, donde dicha composición debe administrarse en los ojos del sujeto una vez por día. De acuerdo con la presente, la administración única de la composición reduce efectivamente la PIO del sujeto durante todo el día.
ARP020103150A 2001-08-23 2002-08-22 Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma AR036276A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31411001P 2001-08-23 2001-08-23

Publications (1)

Publication Number Publication Date
AR036276A1 true AR036276A1 (es) 2004-08-25

Family

ID=23218598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103150A AR036276A1 (es) 2001-08-23 2002-08-22 Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma

Country Status (12)

Country Link
US (1) US20030060511A1 (es)
EP (1) EP1420793A1 (es)
JP (1) JP2004521960A (es)
KR (1) KR20040029012A (es)
CN (1) CN1575178A (es)
AR (1) AR036276A1 (es)
BR (1) BR0205932A (es)
CA (1) CA2458230A1 (es)
MX (1) MXPA04001604A (es)
NO (1) NO20031779L (es)
WO (1) WO2003018025A1 (es)
ZA (1) ZA200302911B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215820A1 (en) * 2002-03-28 2003-10-13 Sucampo Ag Method for treating ocular hypertension and glaucoma
AR043161A1 (es) * 2003-02-14 2005-07-20 Sucampo Pharmaceuticals Inc Composicion oftalmica para tratar hipertension ocular y glaucoma
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP2014510022A (ja) 2011-04-07 2014-04-24 スキャンポ・アーゲー 眼精疲労の処置方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932389A (en) * 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) * 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE03014533T1 (de) * 1988-09-06 2004-07-15 Pharmacia Ab Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
EP0580268B1 (en) * 1988-10-01 1998-01-14 R-Tech Ueno Ltd. Ocular hypotensive agents
TW224942B (es) * 1990-04-04 1994-06-11 Adka Ueno Kk
EP0458588B1 (en) * 1990-05-22 1994-11-30 R-Tech Ueno Ltd. Treatment of ocular hypertension with a synergistic combination for ocular administration
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US6458836B1 (en) * 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension

Also Published As

Publication number Publication date
NO20031779D0 (no) 2003-04-22
CA2458230A1 (en) 2003-03-06
WO2003018025A1 (en) 2003-03-06
EP1420793A1 (en) 2004-05-26
KR20040029012A (ko) 2004-04-03
BR0205932A (pt) 2004-02-17
JP2004521960A (ja) 2004-07-22
CN1575178A (zh) 2005-02-02
MXPA04001604A (es) 2004-07-08
US20030060511A1 (en) 2003-03-27
ZA200302911B (en) 2003-10-14
NO20031779L (no) 2003-04-22

Similar Documents

Publication Publication Date Title
AR039131A2 (es) Metodo para administrar un agente farmaceuticamente activo a un tejido a ser tratado en un cuerpo y metodo para administrar un agente farmaceuticamente activo a un ojo
DK1385452T3 (da) Anordning til tilförsel af et ophthalmisk medikament
UY28709A1 (es) Derivados de prostaglandinas
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
BR0302584A (pt) Combinação de brimonidina e timolol para uso oftálmico tópico
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
ES2189002T3 (es) Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno.
ATE420624T1 (de) Pharmazeutische zusammensetzungen zurbehandlung von augenerkrankungen
Ferris Results of 20 years of research on the treatment of diabetic retinopathy
AR035541A1 (es) Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
BRPI0509220A (pt) método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR036276A1 (es) Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma
DK1621207T3 (da) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
BR0209601A (pt) Método para o tratamento da hipertensão ocular e do glaucoma
IT9086204A1 (it) Metodo per la cura dell'impotenza erettiva maschile
KR910019622A (ko) 안과용 상승적 병용으로 안고혈압의 치료
BR0211545A (pt) Método e composição para tratamento de hipertensão ocular e glaucoma
AR045766A1 (es) Procedimiento mejorado de tratamiento de trastornos del crecimiento
AR121064A1 (es) Cambio de color de ojos por transducción de genes
Goldberg Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 2001; 10: 414-22
Capella et al. Limbal stem cell deficiency following multiple intravitreal injections

Legal Events

Date Code Title Description
FB Suspension of granting procedure